$CLRB
Cellectar Biosciences, Inc.

2017 Q3 Form 10-Q Financial Statement

#000114420417057737 Filed on November 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2016 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.150M $1.160M
YoY Change -0.86% 39.76%
% of Gross Profit
Research & Development $2.333M $1.306M
YoY Change 78.69% 11.8%
% of Gross Profit
Depreciation & Amortization $100.0K $90.00K
YoY Change 11.11% 0.0%
% of Gross Profit
Operating Expenses $2.333M $1.306M
YoY Change 78.69% 11.8%
Operating Profit -$3.484M -$2.468M
YoY Change 41.16% 17.94%
Interest Expense $3.969K $3.116K
YoY Change 27.37% 405.02%
% of Operating Profit
Other Income/Expense, Net $13.07K $181.0K
YoY Change -92.78% -22.73%
Pretax Income -$3.470M -$2.290M
YoY Change 51.53% 23.12%
Income Tax
% Of Pretax Income
Net Earnings -$3.471M -$2.287M
YoY Change 51.77% 23.07%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$2.570M -$4.241M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.660M $5.650M
YoY Change 0.18% 128.74%
Cash & Equivalents $5.717M $5.650M
Short-Term Investments
Other Short-Term Assets $1.030M $500.0K
YoY Change 106.0% -1.96%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $6.690M $6.140M
YoY Change 8.96% 106.54%
LONG-TERM ASSETS
Property, Plant & Equipment $1.500M $1.460M
YoY Change 2.74% -18.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $20.00K
YoY Change -50.0% 68.46%
Total Long-Term Assets $3.180M $3.160M
YoY Change 0.63% -9.42%
TOTAL ASSETS
Total Short-Term Assets $6.690M $6.140M
Total Long-Term Assets $3.180M $3.160M
Total Assets $9.870M $9.300M
YoY Change 6.13% 43.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.020M $1.090M
YoY Change 85.32% 87.93%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $150.0K
YoY Change -100.0% -37.5%
Total Short-Term Liabilities $2.130M $1.430M
YoY Change 48.95% -73.88%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $10.00K
YoY Change -100.0% -93.75%
Other Long-Term Liabilities $140.0K $150.0K
YoY Change -6.67% 0.0%
Total Long-Term Liabilities $140.0K $160.0K
YoY Change -12.5% -47.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.130M $1.430M
Total Long-Term Liabilities $140.0K $160.0K
Total Liabilities $2.280M $1.580M
YoY Change 44.3% -72.67%
SHAREHOLDERS EQUITY
Retained Earnings -$80.27M
YoY Change
Common Stock $135.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.593M $7.720M
YoY Change
Total Liabilities & Shareholders Equity $9.871M $9.300M
YoY Change 6.14% 43.93%

Cashflow Statement

Concept 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income -$3.471M -$2.287M
YoY Change 51.77% 23.07%
Depreciation, Depletion And Amortization $100.0K $90.00K
YoY Change 11.11% 0.0%
Cash From Operating Activities -$2.540M -$2.210M
YoY Change 14.93% 1.84%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K -$10.00K
YoY Change 200.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$30.00K -$10.00K
YoY Change 200.0% 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -80.00K -60.00K
YoY Change 33.33% -68.42%
NET CHANGE
Cash From Operating Activities -2.540M -2.210M
Cash From Investing Activities -30.00K -10.00K
Cash From Financing Activities -80.00K -60.00K
Net Change In Cash -2.650M -2.280M
YoY Change 16.23% -3.8%
FREE CASH FLOW
Cash From Operating Activities -$2.540M -$2.210M
Capital Expenditures -$30.00K -$10.00K
Free Cash Flow -$2.510M -$2.200M
YoY Change 14.09% 1.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
87863106 USD
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80270577 USD
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
7592664 USD
CY2017Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
135 USD
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1150710 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3483768 USD
CY2017Q3 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
9100 USD
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.73
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.02
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13470974 shares
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5368235 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12986435 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3541000 shares
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9871367 USD
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
55000 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1305610 USD
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1162278 USD
CY2016Q3 us-gaap Costs And Expenses
CostsAndExpenses
2467888 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2467888 USD
CY2016Q3 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
177912 USD
CY2016Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3116 USD
CY2017Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3969 USD
CY2017Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
55000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-3470699 USD
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13069 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3310248 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3491259 USD
us-gaap Costs And Expenses
CostsAndExpenses
6801507 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6801507 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
3201004 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
5303 USD
us-gaap Net Income Loss
NetIncomeLoss
-3595200 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3206307 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6365868 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3146605 USD
us-gaap Costs And Expenses
CostsAndExpenses
9512473 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
16625 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
12297 USD
us-gaap Net Income Loss
NetIncomeLoss
-9483551 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
28922 USD
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
294195 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
269317 USD
us-gaap Share Based Compensation
ShareBasedCompensation
573084 USD
us-gaap Share Based Compensation
ShareBasedCompensation
397132 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
411516 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
208387 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8194234 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5933450 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5258 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-346703 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5258 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1786 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2758545 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7726885 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5782392 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3857791 USD
us-gaap Interest Paid Net
InterestPaidNet
364 USD
us-gaap Interest Paid Net
InterestPaidNet
3702 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
6824 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2963259 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
652516 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
86591 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7371121 USD
clrb Payments For Fractional Shares Reverse Stock Splits
PaymentsForFractionalSharesReverseStockSplits
0 USD
clrb Payments For Fractional Shares Reverse Stock Splits
PaymentsForFractionalSharesReverseStockSplits
594 USD
clrb Payments Of Refunds From Deferred Issuance Costs
PaymentsOfRefundsFromDeferredIssuanceCosts
-116337 USD
clrb Payments Of Refunds From Deferred Issuance Costs
PaymentsOfRefundsFromDeferredIssuanceCosts
38569 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
1392000 USD
clrb Number Of Shares Reserved For Future Issuance
NumberOfSharesReservedForFutureIssuance
9661098 shares
CY2016 clrb Number Of Shares Reserved For Future Issuance
NumberOfSharesReservedForFutureIssuance
12321724 shares
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2017Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
8726536 shares
CY2017Q3 us-gaap Share Based Compensation
ShareBasedCompensation
176324 USD
CY2016Q3 us-gaap Share Based Compensation
ShareBasedCompensation
174246 USD
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
246734 shares
CY2017Q3 clrb Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Unvested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedOutstandingNumber
307828 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
246734 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
10.54
CY2017Q3 clrb Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedExercisableWeightedAverageExercisePrice
3.45
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.54
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
21880 USD
CY2017Q3 clrb Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue
25094 USD
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
21880 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y8M8D
clrb Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingWeightedAverageRemainingContractualTerm
P8Y11M12D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
471433 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
112300 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
29167 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y8M8D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.59
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.91
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.48
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
554562 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.6
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
4 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
21420
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
460000 shares
CY2017Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1403000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Current Year
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInCurrentYear
184000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Two
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearTwo
673000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Four
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearFour
72000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Three
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearThree
474000 USD
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000 shares
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000 shares
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13477170 shares
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13477170 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10368325 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10368325 shares
CY2017Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
533065 shares
CY2016Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
At a special meeting held on February 8, 2016, the Company’s stockholders approved an amendment to the Company’s certificate of incorporation to effect a reverse split of the Company’s common stock at a ratio between 1:5 to 1:10 in order to ensure that adequate authorized but unissued shares would be available for anticipated future financings, and to satisfy requirements for the continued listing of the Company’s common stock on the NASDAQ Capital Market. In addition, the proposal approved by the stockholders provided that if the reverse split was effected, the number of shares of common stock that the Company is authorized to issue remained unchanged at 40,000,000. The Company’s stockholders further authorized the board of directors to determine the ratio at which the reverse split would be effected by filing an appropriate amendment to the Company’s certificate of incorporation. The board of directors authorized the ratio of the reverse split and corresponding reduction in authorized shares on February 24, 2016, and effective at the close of business on March 4, 2016, the Company’s certificate of incorporation was amended to effect a 1-for-10 reverse split of the Company’s common stock (the “2016 Reverse Split”). All share and per share numbers included in these consolidated financial statements give effect to the 2016 Reverse Split.
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q3 clrb Share Based Compensation Arrangement By Sharebased Payment Award Options Unvested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedAndExpectedToVestOutstandingNumber
2.42
CY2016Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
55000 USD
CY2016Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
533065 shares

Files In Submission

Name View Source Status
0001144204-17-057737-index-headers.html Edgar Link pending
0001144204-17-057737-index.html Edgar Link pending
0001144204-17-057737.txt Edgar Link pending
0001144204-17-057737-xbrl.zip Edgar Link pending
clrb-20170930.xml Edgar Link completed
clrb-20170930.xsd Edgar Link pending
clrb-20170930_cal.xml Edgar Link unprocessable
clrb-20170930_def.xml Edgar Link unprocessable
clrb-20170930_lab.xml Edgar Link unprocessable
clrb-20170930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv478859_10q.htm Edgar Link pending
tv478859_ex10-3.htm Edgar Link pending
tv478859_ex10-4.htm Edgar Link pending
tv478859_ex31-1.htm Edgar Link pending
tv478859_ex31-2.htm Edgar Link pending
tv478859_ex32-1.htm Edgar Link pending